MedPath
Found 1 clinical trials|View Analysis
Sort by:

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors

Phase 1
Recruiting
Conditions
Locally Advanced, Recurrent or Metastatic Malignancies
Interventions
Drug: SSGJ-705
First Posted Date
2024-04-30
Last Posted Date
2024-10-18
Lead Sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Target Recruit Count
180
Registration Number
NCT06390774
Locations
🇨🇳

Affiliated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China

© Copyright 2025. All Rights Reserved by MedPath